Synthetic Biologics Inc (SYN) Rating Reiterated by William Blair
Synthetic Biologics Inc (NYSEMKT:SYN)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a report issued on Monday. They currently have a $5.00 price target on the stock.
Separately, Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Wednesday, May 10th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Synthetic Biologics has an average rating of “Buy” and an average price target of $4.46.
Shares of Synthetic Biologics (NYSEMKT:SYN) traded up 4.1811% during midday trading on Monday, reaching $0.5407. The company’s stock had a trading volume of 210,851 shares. Synthetic Biologics has a 52 week low of $0.41 and a 52 week high of $2.38. The stock has a 50-day moving average price of $0.52 and a 200 day moving average price of $0.78. The stock’s market capitalization is $65.91 million.
Synthetic Biologics (NYSEMKT:SYN) last announced its quarterly earnings data on Thursday, May 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.05. Equities analysts forecast that Synthetic Biologics will post ($0.21) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG increased its position in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Synthetic Biologics by 2.7% in the first quarter. Geode Capital Management LLC now owns 551,538 shares of the company’s stock valued at $347,000 after buying an additional 14,395 shares during the last quarter. Vanguard Group Inc. boosted its position in Synthetic Biologics by 145.3% in the first quarter. Vanguard Group Inc. now owns 4,429,469 shares of the company’s stock valued at $2,794,000 after buying an additional 2,623,816 shares during the period. Bank of New York Mellon Corp boosted its position in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the period. Finally, Norges Bank bought a new position in Synthetic Biologics during the fourth quarter valued at $356,000.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.